Sofalcone for treatment of Helicobacter pylori infection

Journal of Gastroenterology

Volumn 31, Issue SUPPL. 9, 1996, Pages 56-58

  Fujioka, Toshio ^a   Murakami, Kazunari ^a   Kubota, Toshihiro ^a   Kodama, Reiji ^a   Honda, Shoji ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Antiulcer drug; Gastric mucin; Helicobacter pylori; Sofalcone; Treatment of H. pylori

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BISMUTH NITRATE; CIMETIDINE; CLARITHROMYCIN; ERYTHROMYCIN; FAMOTIDINE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; LANSOPRAZOLE; OMEPRAZOLE; PLAUNOTOL; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SOFALCONE; STOMACH MUCIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; BACTERIUM ADHERENCE; CONFERENCE PAPER; DRUG SAFETY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; LIPOLYSIS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CHALCONE; CHALCONES; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0030475739     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Kyogoku K, Hatayama K, Yokomori S, et al. Anti-ulcer efect of isoprenyl flavonoids. II. Synthesis and anti-ulcer activity of new chalcones related to sophoradin. Chem Pharm Bull (Tokyo) 1979;27:2943-2953.
2. Konturek SJ, Radecki T, Brzozowski T, et al. Antiulcer and gastroprotective effects of solon, a synthetic flavonoid derivative of sophoradin: role of endogenous prostaglandins. Eur J Pharmacol 1986;125:185-192.
3. Sarosiek J, Bilski J, Tsukada H, et al. Effect of solon on gastric mucus viscosity, permeability to hydrogen ion, and susceptibility to pepsin. Digestion 1987;37:238-246.
4. Slomiany BL, Liau YH, Carter SR, et al. Enzymatic sulfation of mucin in gastric mucosa: Effect of sofalcone, sucralfate and aspirin. Digestion 1987;38:178-186.
5. Kodama R, Fujioka T, Fujiyama K, et al. Combination therapy with clarithromycin and sofalcone for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1994;6(Suppl 1):S125-128.
6. Fujioka T, Fujiyama K, Hiramatsu K, Nasu M. In vitro activity of novel proton pump inhibitors against Helicobacter pylori. In: Einhorn J, Nord CE, Norbby SR (eds) Recent advances in chemotherapy. Washington DC: AMS, 1994;612-613.
7. Sunairi M, Watanabe K, Suzuki T, et al. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6(Suppl 1):S121-S124.
8. Slomiany BL, Nishikawa H, Piotrowski J, et al. Lipolytic activity of Campylobacter pylori: Effect of sofalcone. Digestion 1989;43:33-40.
9. Fujioka T, Kubota T, Shuto R, et al. Establishment of an animal model for chronic gastritis with Helicobacter pylori: Potential model for long-term observations. Eur J Gastroenterol Hepatol 1994;6(Suppl 1):S73-S78.
10. Hosking SW, Ling TWK, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: Randomized controlled trial. Lancet 1994;343:508-510
11. Sung JJY, Chung SCS, Ling TWK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-142.
12. Bazzoli F, Zafari RM, Fossi S, et al. Short-term, low-dose triple therapy for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-777.